Top Page
SS Innovations International
(NASDAQ:SSII)
SS Innovations International (SSII) vs. SPDR S&P 500 ETF (SPY)
SS Innovations International Business Overview & Revenue Model
SS Innovations International Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.57M | 20.65M | 5.88M | 1.46M | 0.00 | 0.00 |
| Gross Profit | 16.20M | 8.45M | 713.45K | 489.59K | -18.79K | -37.43K |
| EBITDA | -13.12M | -17.74M | -20.26M | -5.31M | -1.47M | -1.09M |
| Net Income | -17.11M | -19.15M | -20.94M | -5.60M | -1.48M | -1.12M |
Balance Sheet | ||||||
| Total Assets | 69.58M | 42.39M | 25.48M | 8.68M | 428.61K | 317.87K |
| Cash, Cash Equivalents and Short-Term Investments | 5.68M | 466.50K | 7.03M | 1.57M | 405.77K | 160.71K |
| Total Debt | 2.61M | 18.20M | 8.22M | 10.24M | 145.00K | 195.00K |
| Total Liabilities | 29.93M | 28.93M | 11.18M | 11.14M | 287.28K | 1.19M |
| Stockholders Equity | 39.65M | 13.46M | 14.30M | -2.46M | 141.33K | -869.05K |
Cash Flow | ||||||
| Free Cash Flow | -22.02M | -10.16M | -16.34M | -5.78M | -363.03K | -94.54K |
| Operating Cash Flow | -21.05M | -9.50M | -13.57M | -5.56M | -363.03K | -90.54K |
| Investing Cash Flow | -950.51K | -661.48K | -2.30M | -2.74M | 38.15K | -44.00K |
| Financing Cash Flow | 28.20M | 9.43M | 16.73M | 9.29M | 569.95K | 266.77K |
SS Innovations International Technical Analysis
SS Innovations International Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $1.41B | 12.91 | 6.60% | 1.82% | 4.69% | -51.57% | |
61 Neutral | $2.24B | ― | -2.45% | ― | 9.81% | -1066.50% | |
59 Neutral | $1.43B | -16.14 | -338.19% | ― | 24.76% | -10.41% | |
57 Neutral | $900.70M | ― | -111.91% | ― | 25.84% | -47.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $873.95M | ― | -38.71% | ― | 4.99% | -7151.40% | |
44 Neutral | $1.43B | ― | -43.42% | ― | 159.43% | 67.42% |
SS Innovations International Corporate Events
SS Innovations International has released an updated company presentation for November 2025, highlighting their growth and strategic plans. The company has seen significant sales growth and is expanding its global presence, with the SSi Mantra system already marketed in eight countries. The presentation underscores the company’s commitment to improving surgical robotics technology and its potential impact on the healthcare industry.
The most recent analyst rating on (SSII) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
On November 6, 2025, SS Innovations International announced the successful completion of the first telesurgery using its SSi Mantra Tele Surgeon Console (TSC). This compact and portable console allows telesurgeries to be performed from various locations, including physician offices, without the need for a full operating room. The milestone surgery was conducted by Dr. Sudhir Srivastava from New Delhi, India, on a patient in Jaipur, India, highlighting the TSC’s ability to extend surgical expertise remotely. This development is expected to enhance patient access to surgical care and provide hospital networks with greater flexibility.
The most recent analyst rating on (SSII) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
On October 28, 2025, SS Innovations International announced its third-quarter financial results, reporting a 192.5% increase in revenue to $12.8 million, driven by higher sales of the SSi Mantra 3 unit. Despite a net loss of $3.7 million, the company saw significant growth in installations and surgeries, with a 350% increase in SSi Mantra installations compared to the previous year. The company is progressing towards regulatory milestones, including a 510(k) submission to the FDA and a European Union CE marking certification, indicating robust growth prospects.
The most recent analyst rating on (SSII) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
On October 21, 2025, SS Innovations International announced that its executives, Dr. Sudhir Srivastava and Dr. Vishwa Srivastava, will participate in upcoming investor conferences, including the UBS Global Healthcare Conference on November 11, 2025, and the Stifel 2025 Healthcare Conference on November 12, 2025. These events will provide opportunities for one-on-one and small group meetings, and a live webcast of the Stifel presentation will be available on the company’s website. This participation underscores the company’s commitment to engaging with investors and stakeholders, potentially enhancing its industry positioning and visibility.
The most recent analyst rating on (SSII) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
SS Innovations International has released an updated company presentation for October 2025, highlighting its growth and strategic plans. The company has seen significant expansion, with 125 SSi Mantra systems installed and over 6,000 surgeries performed across nine specialties. The presentation underscores the company’s commitment to global expansion, particularly into Europe and the United States, and its strategy for long-term sustainable growth. The leadership team, with a proven track record in surgical robotics, aims to leverage favorable industry trends and a growing market to enhance its positioning and deliver advanced surgical solutions.
The most recent analyst rating on (SSII) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
SS Innovations International announced the successful completion of a human factors validation study for its SSi Mantra surgical robotic system at Johns Hopkins Hospital in September 2025. This milestone is crucial for their anticipated 510(k) premarket notification submission to the FDA in the fourth quarter of 2025, which could potentially allow the SSi Mantra to be marketed in the U.S. by the first half of 2026. The company has installed 125 SSi Mantra systems across six countries, with over 6,000 surgical procedures performed, highlighting its growing global footprint.
The most recent analyst rating on (SSII) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
On September 26, 2025, SS Innovations International announced the appointment of Naveen Kumar Amar as Chief Financial Officer, effective September 24, 2025. Mr. Amar, with over 27 years of global finance experience, brings a strong track record in building finance operations and successful businesses across diverse industries. His appointment is expected to support SS Innovations’ expansion of its advanced, cost-efficient SSi Mantra surgical robotic system and drive growth, enhancing shareholder value.
The most recent analyst rating on (SSII) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
On September 16, 2025, SS Innovations International announced the successful completion of the world’s first pediatric pyeloplasty telesurgery using its SSi Mantra surgical robotic system. This milestone, performed remotely by Dr. Chandra Mohan Vaddi from nearly 1,000 miles away, underscores the system’s potential to enhance precision and accessibility in pediatric surgery. The achievement highlights the company’s commitment to democratizing advanced surgical care, particularly in underserved regions, and positions SS Innovations as a leader in the growing field of robotic telesurgery.
The most recent analyst rating on (SSII) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
On September 9, 2025, SS Innovations International announced the successful completion of the first robotic telesurgery performed from its MantraM mobile robotic telesurgery unit. This milestone, achieved by Dr. Priya Bhave Chittawar, involved a complex hysterectomy conducted remotely in Bhopal, India, highlighting the company’s mission to provide advanced surgical care to underserved populations. The MantraM bus tour, launched in July 2025 across India, aims to demonstrate the capabilities of SS Innovations’ mobile unit and SSi Mantra system, focusing on hospitals and medical institutions in underserved communities.
The most recent analyst rating on (SSII) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
On August 7, 2025, SS Innovations International reported a significant increase in revenue and gross profit for the second quarter of 2025, driven by higher sales of the SSi Mantra 3 robotic system. The company achieved record quarterly revenue of $10 million, a 121.8% increase from the previous year, and gross profit more than tripled due to expanded gross margins. The company also highlighted several pioneering achievements in robotic surgery, including the world’s first robotic telesurgery for weight loss and intercontinental robotic cardiac telesurgery. SS Innovations’ uplisting to Nasdaq and upcoming regulatory submissions are expected to support its global expansion and continued growth.